{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:07:17Z","timestamp":1761664037323},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Behandlungsm\u00f6glichkeiten f\u00fcr Patienten mit metastasierendem Melanom (MM) wurden in den letzten Jahren mit der Zulassung von neuen Medikamenten dramatisch erweitert. Die MEK(mitogen-aktivierte Proteinkinase-Kinasen)- und BRAF(Serin\/Threonin-Kinase B-Raf kodierendes Gen)-Hemmer-Kombinationstherapie geh\u00f6rt aktuell zum Versorgungsstandard f\u00fcr das Stadium IIIC\/IV des BRAF-mutierten Melanoms. MEKAR (MEK-Inhibitor-assoziierte Retinopathie) werden bei Patienten mit metastasierendem Melanom beobachtet, die mit einer solchen Kombinationstherapie behandelt werden bzw. wurden. Wir berichten \u00fcber den Fall eines 72-j\u00e4hrigen Patienten, der eine solche Pathologie unter der Therapie mit Binimetinib in Kombination mit Nivolumab erlitt. Diese Kasuistik verdeutlicht die Wichtigkeit einer interdisziplin\u00e4ren Zusammenarbeit bei der Behandlung von MM-Patienten.<\/jats:p>","DOI":"10.1007\/s00347-020-01089-3","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T16:02:26Z","timestamp":1586016146000},"page":"169-174","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom"],"prefix":"10.1007","volume":"118","author":[{"given":"S.","family":"Groselli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. P.","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"1089_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00347-017-0459-1","volume":"114","author":"RS Grajewski","year":"2017","unstructured":"Grajewski\u00a0RS, Heindl\u00a0LM (2017) Paraneoplastic serous retinopathies: hormones, mediators, and inhibitors. Ophthalmologe 114:377\u2013378","journal-title":"Ophthalmologe"},{"key":"1089_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00417-013-2563-5","volume":"252","author":"RS Grajewski","year":"2014","unstructured":"Grajewski\u00a0RS, Schuler-Thurner\u00a0B, Mauch\u00a0C, Kreuzberg\u00a0N, Koch\u00a0KR, Bergua\u00a0A, Cursiefen\u00a0C, Heindl\u00a0LM (2014) Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers. Graefes Arch Clin Exp Ophthalmol 252:679\u2013685","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1089_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2478\/raon-2018-0002","volume":"52","author":"AU Gavric","year":"2018","unstructured":"Gavric\u00a0AU, Ocvirk\u00a0J, Mekjavic\u00a0PJ (2018) Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib. Radiol Oncol 52:213\u2013219","journal-title":"Radiol Oncol"},{"issue":"12","key":"1089_CR4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","volume":"124","author":"JH Francis","year":"2017","unstructured":"Francis\u00a0JH, Habib\u00a0L, Abramson\u00a0DH, Yannuzzi\u00a0LA, Heinemann\u00a0M, Gounder\u00a0MM, Grisham\u00a0RN, Postow\u00a0MA, Shoushtari\u00a0AN, Chi\u00a0P, Yaeger\u00a0R, Ho\u00a0AL, Chapman\u00a0PB, Catalanotti\u00a0F, Segal\u00a0NH (2017) Clinical and morphologic characteristics of MEK inhibitorassociated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124(12):1788\u20131798","journal-title":"Ophthalmology"},{"key":"1089_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00347-016-0226-8","volume":"113","author":"I Ludeke","year":"2016","unstructured":"Ludeke\u00a0I, Terheyden\u00a0P, Grisanti\u00a0S, Luke\u00a0M (2016) Development of serous retinopathy during therapy of a\u00a0metastatic cutaneous melanoma. Ophthalmologe 113:861\u2013863","journal-title":"Ophthalmologe"},{"key":"1089_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke\u00a0JJ, Flaherty\u00a0KT, Ribas\u00a0A, Long\u00a0GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14:463\u2013482","journal-title":"Nat Rev Clin Oncol"},{"key":"1089_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00347-016-0271-3","volume":"114","author":"N Kellermann","year":"2017","unstructured":"Kellermann\u00a0N, Maier\u00a0M, Feucht\u00a0N (2017) Vitreous metastasis of malignant cutaneous melanoma during treatment with ipilimumab. Ophthalmologe 114:163\u2013166","journal-title":"Ophthalmologe"},{"key":"1089_CR8","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2014) S3-Leitlinie Pr\u00e4vention von Hautkrebs, Langversion 1.1. http:\/\/leitlinienprogrammonkologie.de\/Leitlinien.7.0.html. Zugegriffen: 5. Jan. 2020 (AWMF Registernummer: 032\/052OL)"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01089-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-020-01089-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01089-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T23:19:44Z","timestamp":1617491984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-020-01089-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s00347-020-01089-3","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,4]]},"assertion":[{"value":"4 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Groselli, D.\u00a0Heinrich, C.P.\u00a0Lohmann und M.\u00a0Maier geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}